#Switzerland #Geneva #MindMaze #Neurorehabilitation #MindMotion Lite

MindMaze Therapeutics Announces MindMotion Lite

MindMaze Therapeutics is set to revolutionize home-based neurorehabilitation with its innovative product, MindMotion Lite, expected to launch by the end of 2026. This new solution is designed to deliver personal neurotherapeutic activities using a tablet, significantly making the process more accessible for patients recuperating at home.

Meeting a Critical Need

In the world of neurorehabilitation, access to effective therapy after leaving a hospital can often pose a challenge. Patients recovering from strokes, as highlighted by recent updates to the AHA/ASA guidelines, require continuous and intensive rehab efforts to achieve optimal recovery. However, the reality is that many patients find themselves without the necessary support once they return home. MindMotion Lite aims to fill this critical gap by offering a portable solution that patients can use comfortably in their own environments.

Accessibility and Use Experience

MindMotion Lite grants users access to the extensive array of neurotherapeutic activities previously available only through the company’s MindMotion GO system. By shifting from complex hardware to a more user-friendly tablet format, MindMaze enhances usability and streamlines home deployment. Patients will be able to engage in full-body rehabilitation exercises designed to keep them motivated and committed to their recovery journey.

Moreover, the tablet’s teleconsultation capabilities allow healthcare professionals to monitor and support patients remotely, ensuring continuity of care that extends beyond the clinic walls. Zach Henderson, CEO of MindMaze, emphasizes that the goal is to make intensive neurorehabilitation a routine part of patients’ lives, ensuring that they continue progressing even after formal hospital care has ended.

Innovative Integration with Existing Technology

The launch of MindMotion Lite will complement MindMaze’s existing platform, which integrates therapeutic software, sensors, and specialized hardware to create a coherent rehabilitation experience across various care stages. The tablet-based approach not only reduces the costs associated with deploying these solutions at home but also improves patient interactions with the technology, making the recovery process engaging and accessible.

As noted by Henderson, it’s not just about providing a new product but rather creating an entire ecosystem of care that is integrated within existing reimbursement frameworks. This support will empower both patients and providers, further strengthening the effectiveness of the neurorehabilitation experience.

Preview at Upcoming Events

Prior to its launch, MindMaze will showcase MindMotion Lite at several industry conferences, allowing stakeholders, healthcare professionals, and potential users to explore the technology firsthand. This event will provide crucial insights into the features and benefits of the product as MindMaze gears up for a full-scale rollout.

About MindMaze Therapeutics

MindMaze Therapeutics (SIX: MMTX) is renowned for its commitment to precision neurotherapeutics, aimed at changing the recovery landscape for neurological disorders worldwide. The company blends advanced software, proprietary sensors, and AI capabilities to create a seamless continuum of care from hospitalization to outpatient and home-based therapy. With products that are both FDA-listed and CE-marked, MindMaze focuses on addressing the shortage of specialized medical professionals, offering scalable, reimbursable solutions for conditions like stroke and Parkinson's disease.

For additional updates, visit MindMaze’s website or follow MindMaze Therapeutics at upcoming conferences to learn more about their transformative technologies.

MindMaze Therapeutics is pioneering the future of neurorehabilitation, ensuring that access to technology-driven care remains a reality for patients everywhere.